Teladoc Health (NYSE:TDOC) Sets New 52-Week Low – Time to Sell?

Teladoc Health, Inc. (NYSE:TDOC) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $6.34 and last traded at $6.3250, with a volume of 4744722 shares traded. The stock had previously closed at $6.53.

Wall Street Analysts Forecast Growth

TDOC has been the topic of a number of research reports. BMO Capital Markets assumed coverage on Teladoc Health in a research report on Thursday, November 13th. They set a “market perform” rating and a $8.00 price target on the stock. Evercore ISI lowered their price objective on Teladoc Health from $9.00 to $8.00 and set an “in-line” rating for the company in a research note on Thursday, October 30th. Zacks Research lowered Teladoc Health from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Weiss Ratings reissued a “sell (e+)” rating on shares of Teladoc Health in a report on Monday, December 29th. Finally, Citigroup lowered their price target on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating for the company in a research report on Friday, January 9th. Five investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $9.50.

Teladoc Health Price Performance

The company has a market capitalization of $1.11 billion, a price-to-earnings ratio of -4.89 and a beta of 2.04. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.70 and a quick ratio of 2.60. The business has a fifty day moving average price of $7.26 and a 200 day moving average price of $7.75.

Teladoc Health (NYSE:TDOC) last posted its quarterly earnings data on Wednesday, October 29th. The health services provider reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.05. The business had revenue of $626.44 million during the quarter, compared to the consensus estimate of $625.66 million. Teladoc Health had a negative net margin of 8.84% and a negative return on equity of 10.59%. The company’s quarterly revenue was down 2.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.19) earnings per share. Teladoc Health has set its Q4 2025 guidance at -0.250–0.100 EPS. On average, research analysts expect that Teladoc Health, Inc. will post -1.16 earnings per share for the current fiscal year.

Insider Activity at Teladoc Health

In other news, insider Adam C. Vandervoort sold 5,720 shares of Teladoc Health stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $7.49, for a total transaction of $42,842.80. Following the transaction, the insider directly owned 80,732 shares in the company, valued at approximately $604,682.68. This trade represents a 6.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Charles Divita III sold 17,138 shares of the business’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the sale, the chief executive officer directly owned 201,036 shares in the company, valued at $1,533,904.68. This represents a 7.86% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 33,288 shares of company stock worth $251,684 over the last ninety days. Insiders own 0.58% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Teladoc Health by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 21,910,950 shares of the health services provider’s stock valued at $169,372,000 after purchasing an additional 891,732 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Teladoc Health by 23.8% during the third quarter. Dimensional Fund Advisors LP now owns 6,889,194 shares of the health services provider’s stock valued at $53,260,000 after purchasing an additional 1,325,106 shares during the last quarter. Geode Capital Management LLC lifted its stake in Teladoc Health by 2.1% during the second quarter. Geode Capital Management LLC now owns 4,150,197 shares of the health services provider’s stock valued at $36,153,000 after purchasing an additional 84,356 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Teladoc Health by 11.1% during the third quarter. Ameriprise Financial Inc. now owns 2,284,697 shares of the health services provider’s stock worth $17,661,000 after buying an additional 227,385 shares in the last quarter. Finally, Allianz Asset Management GmbH grew its position in Teladoc Health by 189.2% in the third quarter. Allianz Asset Management GmbH now owns 1,619,391 shares of the health services provider’s stock worth $12,518,000 after buying an additional 1,059,458 shares during the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.